Sodium-glucose cotransporter-2 inhibitors (SGLT2i), widely used in the management of diabetes mellitus (DM), chronic kidney disease (CKD), and congestive heart failure (CHF), promote urinary glucose excretion, potentially fostering an environment favorable to bacterial and fungal growth. This evidence concerns the gene SLC5A2 and congestive heart failure.